NBIX Latest Press Releases

-- October 26, 2026 --

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia PRNewswire 8:31 AM

-- October 22, 2026 --

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome PRNewswire 4:05 PM

-- October 21, 2026 --

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market Globe Newswire 10:40 AM

-- October 20, 2026 --

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease PRNewswire 8:30 AM

-- October 16, 2026 --

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia PRNewswire 8:31 AM

-- October 12, 2026 --

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results PRNewswire 4:01 PM

-- September 30, 2026 --

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference PRNewswire 8:30 AM

-- September 28, 2026 --

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer PRNewswire 4:05 PM

-- September 2, 2026 --

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PRNewswire 4:01 PM

-- August 12, 2026 --

Neurocrine Biosciences Announces Publication of KINECT-PRO Findings Demonstrating INGREZZA (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia PRNewswire 8:30 AM

-- August 7, 2026 --

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist PRNewswire 8:30 AM

-- July 30, 2026 --

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 23, 2026 --

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions PRNewswire 4:05 PM

-- July 21, 2026 --

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer PRNewswire 4:05 PM

-- July 9, 2026 --

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 1, 2026 --

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia PRNewswire 4:05 PM

-- June 15, 2026 --

Soleno Therapeutics Presents New VYKAT XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period PRNewswire 4:11 PM

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11-Hydroxylase Deficiency at ENDO 2026 PRNewswire 4:05 PM

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PRNewswire 8:35 AM

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PRNewswire 8:30 AM

-- June 8, 2026 --

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA (valbenazine) Capsules Across a Broad Range of Patients PRNewswire 4:05 PM

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities PRNewswire 8:30 AM

-- June 3, 2026 --

Neurocrine Biosciences to Present New Two-Year CRENESSITY (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026 PRNewswire 8:30 AM

Market Data Delayed 15 Minutes